BERWYN, Pa.--(BUSINESS WIRE)--QR Pharma, Inc. (QR), a clinical stage specialty pharmaceutical company committed to developing therapeutics with novel approaches for the treatment of Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative disorders, announced today that Dr. Maria Maccecchini, CEO, will be presenting new data on its lead compound "Posiphen® Recovers Memory, Learning and Brain Function in Alzheimer Transgenic Mice" at the 12th Annual Biotech Symposium, taking place October 22, 2012 in Philadelphia, PA. Alzheimer’s disease is a debilitating disease characterized pathologically by plaques and tangles in the brain. These deposits contain the toxic proteins Ab42 and phospho-Tau. Posiphen inhibits the synthesis of these two toxic proteins and reverses cognitive decline and synaptic dysfunction, making it a promising drug to treat neurodegenerative disorders such as Alzheimer’s and Parkinson’s disease.
